Harvest Management LLC Has $422,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Harvest Management LLC lessened its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 4.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,300 shares of the company’s stock after selling 400 shares during the quarter. Harvest Management LLC’s holdings in Janux Therapeutics were worth $422,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Summit Securities Group LLC purchased a new stake in Janux Therapeutics during the 2nd quarter valued at about $29,000. Amalgamated Bank lifted its stake in shares of Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares during the period. Plato Investment Management Ltd purchased a new stake in shares of Janux Therapeutics during the 2nd quarter worth about $42,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics in the second quarter valued at about $151,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the transaction, the chief executive officer now owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. This trade represents a 7.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the sale, the insider now owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. This trade represents a 3.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 445,610 shares of company stock worth $20,578,666 over the last three months. 29.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. Scotiabank decreased their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Leerink Partners began coverage on shares of Janux Therapeutics in a research report on Friday, November 22nd. They set an “outperform” rating and a $79.00 price target for the company. Finally, Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and an average price target of $67.70.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $40.18 on Tuesday. The firm has a 50-day moving average of $49.81 and a 200-day moving average of $45.77. Janux Therapeutics, Inc. has a one year low of $7.79 and a one year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The business’s quarterly revenue was down 82.6% compared to the same quarter last year. Analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.